XNAS
LNAI
Market cap25mUSD
Oct 08, Last price
1.12USD
1D
2.75%
1Q
-61.90%
Jan 2017
-90.67%
IPO
-97.67%
Name
Enochian Biosciences Inc
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
20.71%
Rev. gr., 5y
%
Revenues
0
Net income
-178m
L+101.31%
CFO
-8m
L-28.23%
Earnings
Oct 09, 2026
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Enochian Biosciences, Inc. is a pre-clinical biotechnology firm dedicated to the research and advancement of novel pharmaceutical and biological agents. Its primary focus lies in developing treatments for a range of human diseases, including human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza, coronavirus infections, and various cancers. The company's leading investigational products encompass ENOB-HV-01, an autologous therapy aimed at achieving an HIV cure; ENOB-HV-11, a preventative HIV vaccine candidate; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, which targets the HBV polymerase. Beyond these primary programs, Enochian Biosciences' developmental pipeline also features ENOB-DC-11, an off-the-shelf dendritic cell vaccine designed for multiple solid tumors, and ENOB-DC-21, a non-specific vaccine intended for direct intratumoral injection. The company collaborates strategically with prominent research organizations such as The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. Founded in 2017, Enochian Biosciences, Inc. operates from its headquarters in Los Angeles, California.
Key people
Eric Jean Marie Patterson Leire
Chief Executive Officer · since 2017
Mark Dybul
Executive Vice Chairman of the Board · since 2019
Luisa Puche
Chief Financial Officer, IR Contact Officer · since 2019
Principal Accounting Officer, Chief Accounting Officer · since 2019
Director · since 2019
Director · since 2019
Henrik Gronfeldt-Sorensen
Director · since 2017
Jacob Rosenberg
Director · since 2014
Rene Sindlev
Independent Director · since 2017
Legal address
C/O Vcorp Services, LLC
108 W. 13TH STREET
SUITE 100
Wilmington, DE 19801
US
108 W. 13TH STREET
SUITE 100
Wilmington, DE 19801
US
Headquarters
C/O DanDrit Biotech A/S
Box 62
Symbion Science Park
Fruebjergvej 3
Copenhagen, 84 2100
DK
Box 62
Symbion Science Park
Fruebjergvej 3
Copenhagen, 84 2100
DK
Previous name
DanDrit Biotech USA, Inc.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||